Overview

  • Product name
  • Description
    Rabbit polyclonal to Tau
  • Host species
    Rabbit
  • Specificity
    ab64193 recognizes both non-phosphorylated and phosphorylated Ser262.
  • Tested applications
    Suitable for: ICC, WB, Dot blot, ICC/IF, IHC-FoFrmore details
    Unsuitable for: IHC-P
  • Species reactivity
    Reacts with: Mouse, Cow, Human, Zebrafish, Apteronotus leptorhynchus
    Predicted to work with: Rat
  • Immunogen

    Synthetic peptide corresponding to Human Tau aa 576-583.
    Sequence:

    KIGSTENL

  • Positive control
    • Recombinant Human Tau412 protein (ab125484) can be used as a positive control in WB. Mouse brain tissue lysate.

Properties

Applications

Our Abpromise guarantee covers the use of ab64193 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC Use at an assay dependent concentration.
WB Use a concentration of 0.5 - 2 µg/ml. Detects a band of approximately 52 kDa (predicted molecular weight: 79 kDa).
Dot blot Use a concentration of 0.5 - 2 µg/ml. By dot blot, this antibody only recognizes the immunizing peptide.
ICC/IF Use at an assay dependent concentration.
IHC-FoFr Use at an assay dependent concentration.
  • Application notes
    Is unsuitable for IHC-P.
  • Target

    • Function
      Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
    • Tissue specificity
      Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.
    • Involvement in disease
      Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).
      Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
      Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
      Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
      Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.
    • Sequence similarities
      Contains 4 Tau/MAP repeats.
    • Developmental stage
      Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
    • Domain
      The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
    • Post-translational
      modifications
      Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.
      Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
      Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
    • Cellular localization
      Cytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
    • Information by UniProt
    • Database links
    • Form
      There are 9 isoforms produced by alternative splicing.
    • Alternative names
      • AI413597 antibody
      • AW045860 antibody
      • DDPAC antibody
      • FLJ31424 antibody
      • FTDP 17 antibody
      • G protein beta1/gamma2 subunit interacting factor 1 antibody
      • MAPT antibody
      • MAPTL antibody
      • MGC134287 antibody
      • MGC138549 antibody
      • MGC156663 antibody
      • Microtubule associated protein tau antibody
      • Microtubule associated protein tau isoform 4 antibody
      • Microtubule-associated protein tau antibody
      • MSTD antibody
      • Mtapt antibody
      • MTBT1 antibody
      • MTBT2 antibody
      • Neurofibrillary tangle protein antibody
      • Paired helical filament tau antibody
      • Paired helical filament-tau antibody
      • PHF tau antibody
      • PHF-tau antibody
      • PPND antibody
      • PPP1R103 antibody
      • Protein phosphatase 1, regulatory subunit 103 antibody
      • pTau antibody
      • RNPTAU antibody
      • TAU antibody
      • TAU_HUMAN antibody
      • Tauopathy and respiratory failure, included antibody
      see all

    Images

    • Anti-Tau antibody (ab64193) at 1/100 dilution + Mouse brian whole tissue lysate at 120 µg

      Secondary
      HRP-conjugated goat anti-rabbit IgG polyclonal at 1/10000 dilution

      Developed using the ECL technique.

      Performed under reducing conditions.

      Predicted band size: 79 kDa
      Observed band size: 52 kDa
      why is the actual band size different from the predicted?


      Exposure time: 5 minutes

      See Abreview

    • Immunohistochemical analysis of Apteronotus leptorhynchus brain tissue, staining Tau with ab64193.

      Tissue was fixed with paraformaldehyde, permeabilized with 0.3% Triton X-100 and blocked with 3% sheep serum (ab7489), 1% BSA and 1% teleostean gelatine in TBS for 1 hour at 24°C. Samples were incubated with primary antibody (1/20 in blocking solution) for 18 hours at 4°C. An AlexaFluor®546-conjugated goat anti-rabbit polyclonal IgG (1/200) was used as the secondary antibody.

      See Abreview

    • Immunocytochemistry of Zebrafish Cultured Cells (primary neuron), labelling Tau with ab64193.

    • Immunocytochemistry/ Immunofluorescence analysis of mouse primary cortical neuronal cells abeling Tau with ab64193 at a dilution of 1/100. The cells were fixed with Ethanol and permeabilized with 0.2% Triton X-100.  An AlexaFluor®488-conjugated goat anti-rabbit polyclonal IgG (1/200) was used as the secondary antibody.

      See Abreview

    • Anti-Tau antibody (ab64193) at 1/200 dilution + Mouse brain tissue lysate at 15 µg

      Predicted band size: 79 kDa
      Observed band size: 52 kDa why is the actual band size different from the predicted?

    References

    This product has been referenced in:
    • Yi S  et al. Tau modulates Schwann cell proliferation, migration and differentiation following peripheral nerve injury. J Cell Sci 132:N/A (2019). Read more (PubMed: 30782778) »
    • Losev Y  et al. Novel model of secreted human tau protein reveals the impact of the abnormal N-glycosylation of tau on its aggregation propensity. Sci Rep 9:2254 (2019). Read more (PubMed: 30783169) »
    See all 39 Publications for this product

    Customer reviews and Q&As

    Filter by Application

    Filter by Species

    Filter by Ratings

    1-8 of 8 Abreviews

    Application
    Immunocytochemistry/ Immunofluorescence
    Sample
    Mouse Cell (Primary cortical neuronal cells)
    Permeabilization
    Yes - 0.2% Triton X-100
    Specification
    Primary cortical neuronal cells
    Blocking step
    casein solution + Tween 20 as blocking agent for 20 minute(s) · Concentration: 0.2% · Temperature: 25°C
    Fixative
    Ethanol

    Abcam user community

    Verified customer

    Submitted Aug 26 2016

    Abreviews
    Application
    Western blot
    Loading amount
    120 µg
    Gel Running Conditions
    Reduced Denaturing (15)
    Sample
    Mouse Tissue lysate - whole (Brain)
    Specification
    Brain
    Blocking step
    Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C

    Abcam user community

    Verified customer

    Submitted Apr 16 2014

    Application
    Immunocytochemistry/ Immunofluorescence
    Blocking step
    BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
    Sample
    Mouse Cell (Primary neuronal cells)
    Specification
    Primary neuronal cells
    Permeabilization
    Yes - Triton-X
    Fixative
    Paraformaldehyde

    Abcam user community

    Verified customer

    Submitted Oct 08 2013

    Application
    Immunohistochemistry (PFA perfusion fixed frozen sections)
    Sample
    Apteronotus leptorhynchus Tissue sections (Brain)
    Specification
    Brain
    Fixative
    Paraformaldehyde
    Antigen retrieval step
    None
    Permeabilization
    Yes - 0.3% Triton X-100
    Blocking step
    3% sheep serum, 1% BSA, 1% teleostean gelatine in TBS as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 24°C

    Abcam user community

    Verified customer

    Submitted Nov 26 2012

    Application
    Western blot
    Sample
    Apteronotus leptorhynchus Tissue lysate - whole (Brain)
    Loading amount
    50 µg
    Specification
    Brain
    Gel Running Conditions
    Reduced Denaturing (4-15%)
    Blocking step
    Milk as blocking agent for 14 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 4°C

    Abcam user community

    Verified customer

    Submitted Nov 26 2012

    Abreviews
    Application
    Western blot
    Sample
    Mouse Cell lysate - whole cell (neuronal)
    Loading amount
    30 µg
    Specification
    neuronal
    Gel Running Conditions
    Reduced Denaturing (10)
    Blocking step
    (agent) for 1 hour(s) and 0 minute(s) · Concentration: 100% · Temperature: 20°C

    Abcam user community

    Verified customer

    Submitted Oct 12 2012

    This product is known to not work in this application or species.
    Application
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Sample
    Mouse Tissue sections (Brain)
    Specification
    Brain
    Fixative
    Formaldehyde
    Antigen retrieval step
    Heat mediated - Buffer/Enzyme Used: Citric acid HIER
    Permeabilization
    No
    Blocking step
    BSA as blocking agent for 10 minute(s) · Concentration: 1% · Temperature: 21°C

    Mr. Carl Hobbs

    Verified customer

    Submitted Nov 02 2010

    Application
    Immunocytochemistry
    Sample
    Zebrafish Cultured Cells (primary neuron)
    Specification
    primary neuron
    Fixative
    Paraformaldehyde
    Permeabilization
    Yes - 0.1% Triton-X-100
    Blocking step
    Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 20°C

    Abcam user community

    Verified customer

    Submitted Jan 29 2009

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up